Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Open Orphan Plc ( (GB:HVO) ) has provided an update.
hVIVO plc, a specialist clinical development partner and global leader in human challenge trials, focuses on accelerating vaccine and therapeutic development for major biopharma clients through integrated consulting, clinical, challenge trial, and laboratory services. Its proprietary human challenge models, large volunteer database via FluCamp, and dedicated quarantine and lab facilities underpin a strong position in infectious and respiratory disease research.
The company has secured a £6m contract with a clinical-stage biopharmaceutical client to run an influenza human challenge trial testing a monoclonal antibody, using its Influenza Human Challenge Study Model in Canary Wharf facilities. The study, due to start in 2026 with revenue recognised across 2026 and 2027, strengthens hVIVO’s revenue visibility and showcases the value of its end-to-end recruitment, clinical and virology capabilities amid ongoing global healthcare pressures from seasonal influenza.
The most recent analyst rating on (GB:HVO) stock is a Buy with a £10.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.
Spark’s Take on HVO Stock
According to Spark, TipRanks’ AI Analyst, HVO is a Neutral.
The score is held back primarily by the latest financial deterioration (losses, negative gross profit, and significant cash flow weakness). Offsetting this are moderately positive technical momentum signals and earnings-call indications of improving demand/pipeline, though liquidity and booking visibility remain key near-term risks.
To see Spark’s full report on HVO stock, click here.
More about Open Orphan Plc
hVIVO plc is a UK-based, full-service international clinical development partner and the global leader in human challenge trials, working with seven of the world’s ten largest biopharma companies. The Group offers an end-to-end platform from preclinical strategy through Phase II trials and specialist laboratory services, leveraging owned quarantine facilities, labs, and its FluCamp recruitment arm in the UK and Germany.
Its operations span four integrated service lines: Consulting for preclinical and clinical strategy, Clinical Trials for Phase I–III studies and recruitment, Human Challenge Trials using its large London quarantine facility, and Laboratories providing advanced virology and immunology services. This integrated model is designed to accelerate time to clinical proof-of-concept for vaccines and therapeutics, particularly in infectious and respiratory diseases.
Average Trading Volume: 3,839,262
Technical Sentiment Signal: Sell
Current Market Cap: £50.25M
Find detailed analytics on HVO stock on TipRanks’ Stock Analysis page.